"This modification stabilizes tau levels in human cells and mouse neurons by making it resistant to autophagy ... their potential effects in Alzheimer's disease and tau-induced dementias." ...

One of the key features of Alzheimer’s disease is an accumulation of a harmful protein called tau. In a healthy brain, tau primarily helps to support and stabilise brain cells (neurons).

Tau is a protein that builds up and moves between nerve cells in the brains of people living with Alzheimer’s disease, causing damage. Professor Mudher is using clever genetic manipulation in fruit ...

P-tau 217 had high accuracy in diagnosing Alzheimer’s disease. P-tau 217 could also be a useful tool for detecting AD neuropathology in syndromes not commonly associated with AD. Phosphorylated ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

Early work revealed that TFEB is highly effective in ameliorating tau/NFT pathology and rescuing cognitive impairment and neurodegeneration. TFEB targets only the aberrant tau species and this ...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...

Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for detecting tau tangles in the brain, a hallmark of Alzheimer's disease.

Finally, a few studies in mice have found that the medications can reduce the buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup ...

Blarcamesine works by enhancing autophagy through SIGMAR1 activation, addressing the underlying pathology of Alzheimer's disease before the onset of amyloid beta and tau tangles. The treatment ...